Search Results

Medeor Therapeutics announced positive interim data from its multicenter, international Phase III clinical trial.

Medeor Therapeutics announced that it will present interim Phase 3 data investigating if MDR-101 cell therapy can safely induce immune tolerance and eliminate the need for immunosuppressive drugs vs. standard of care following a kidney transplant as a late-breaking oral presentation at the American Society of Nephrology Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced the appointment of Daniel Brennan, MD, as Chief Medical Officer. In his role, Dr. Brennan will oversee the clinical development program fo

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that interim results of ts Phase 3 study clinical trial for MDR-101 cell therapy

Medeor Therapeutics, Inc. announced that interim results from the company’s MERCURY Phase 3 clinical trial will be presented by lead Principal Investigator Dr. Dixon Kaufman of the University of Wisconsin at the American Society of Nephrology Kidney Week 2020, being held virtually from October 19-25, 2020.